365 related articles for article (PubMed ID: 21247857)
1. [Differentiated thyroid cancer -- 2009].
Konrády A
Orv Hetil; 2011 Jan; 152(5):163-70. PubMed ID: 21247857
[TBL] [Abstract][Full Text] [Related]
2. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
[TBL] [Abstract][Full Text] [Related]
4. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
6. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
7. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
8. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
[TBL] [Abstract][Full Text] [Related]
9. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
[TBL] [Abstract][Full Text] [Related]
10. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up.
Salvatori M; Biondi B; Rufini V
Eur J Endocrinol; 2015 Sep; 173(3):R115-30. PubMed ID: 25947140
[TBL] [Abstract][Full Text] [Related]
11. [Taking of position in relationship to the protocol of the current treatment of thyroid nodules and differentiated thyroid cancer].
Gómez Sáez JM
Endocrinol Nutr; 2010 Oct; 57(8):370-5. PubMed ID: 20850397
[No Abstract] [Full Text] [Related]
12. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
13. Role of 131I in the treatment of well differentiated thyroid cancer.
Woodrum DT; Gauger PG
J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
[TBL] [Abstract][Full Text] [Related]
14. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
15. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
Schlumberger MJ; Incerti C; Pacini F; Reiners C
J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
[TBL] [Abstract][Full Text] [Related]
16. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of differentiated thyroid carcinoma.
Cox AE; LeBeau SO
Radiol Clin North Am; 2011 May; 49(3):453-62, vi. PubMed ID: 21569904
[TBL] [Abstract][Full Text] [Related]
18. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
19. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.
Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E
Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849
[TBL] [Abstract][Full Text] [Related]
20. Thyroid cancer.
Carling T; Udelsman R
Annu Rev Med; 2014; 65():125-37. PubMed ID: 24274180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
